🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

875 results for “A.” Clear

  1. Ilumetri 100 mg solution for injection in pre-filled syringe, tildrakizumab placebo solution for injection in pre-filled syringe

    Pharma Mar S.A.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  2. Imnovid 3 mg hard capsules, DARZALEX 20 mg/mL concentrate for solution for infusion, Bortezomib Fresenius Kabi 3.5 mg powder for solution for injection, DARZALEX 20 mg/mL concentrate for solution for infusion, Kyprolis 30 mg powder for solution for infusion, Kyprolis 60 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Neofordex 40 mg tablets, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Kyprolis 10 mg powder for solution for infusion, Anitocabtagene autoleucel, Bortezomib Freseniu

    Pharma Mar S.A.

    Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

    phase 3 small molecule active

    1 trial

  3. Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Dexamethasone Tablets BP 2.0mg, Dexamethason 8 mg GALEN® Tabletten, Imnovid 2 mg hard capsules, Dexamethason 8 mg JENAPHARM®, Dexamethasone 2mg Tablets, Imnovid 1 mg hard capsules, VELCADE 3.5 mg powder for solution for injection

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  4. Impetine® 20mg/g Gel, Bactroban 20 mg/g pomada

    Pharma Mar S.A.

    Impetigo

    phase 3 small molecule active

    1 trial

  5. Isotone Kochsalz-Lösung 0,9 % Braun Infusionslösung, Panzyga 100 mg/ml Infusionslösung

    Maze Therapeutics

    Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia.

    phase 3 small molecule active

    1 trial

  6. JEMPERLI 500 mg concentrate for solution for infusion, Docetaxel Hikma 20 mg/1 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel Hikma 160 mg/8 ml Konzentrat zur Herstellung einer Infusionslösung

    GlaxoSmithKline Biologicals S.A.

    Lung Cancer, Non-Small Cell

    phase 3 small molecule active

    1 trial

  7. JNJ 67896062, Matching Placebo for Macitentan 75 mg, JNJ 67896062, Matching Placebo for Macitentan 37.5 mg, Opsumit 10 mg film-coated tablets, Matching Placebo for Macitentan 10 mg

    Pharma Mar S.A.

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  8. JNJ-67896049, JNJ-67896049, Opsumit 10 mg film-coated tablets, JNJ-68150420, JNJ-67896049

    Pharma Mar S.A.

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  9. JNJ-67896062, JNJ-67896062

    Pharma Mar S.A.

    Pediatric pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  10. JR-141

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  11. JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

    Pharma Mar S.A.

    Mucopolysaccharidosis type II, Hunter Syndrome

    phase 3 small molecule active

    1 trial

  12. JX10, Jx10 placebo drug product is prepared as a sterile, lyophilized white to light yellow cake or powder for infusion.

    Pharma Mar S.A.

    Acute ischemic stroke

    phase 3 small molecule active

    1 trial

  13. JZP258

    Pharma Mar S.A.

    Narcolepsy

    phase 3 small molecule active

    1 trial

  14. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets

    Alfasigma S.p.A.

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  15. Jyseleca 100 mg film-coated tablets, Jyseleca 200 mg film-coated tablets, Composition apart from the active substance otherwise to identical to IMP

    Alfasigma S.p.A.

    Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  16. Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets, GLPG0634

    Alfasigma S.p.A.

    Polyarticular-course juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  17. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  18. KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 734506

    Ology Bioservices Ireland LTD

    Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

    phase 3 small molecule active

    1 trial

  19. KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMBROLIZUMAB, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Saline bag, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp Alfa, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Ficerafusp A

    Bicara Therapeutics

    Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

    phase 3 small molecule active

    1 trial

  20. KEYTRUDA 25 mg/mL concentrate for solution for infusion, LIBTAYO 350 mg concentrate for solution for infusion., Placebo for Fianlimab, Fianlimab

    Pharma Mar S.A.

    Melanoma

    phase 3 small molecule active

    1 trial

  21. KIg10

    Kedrion S.p.A.

    Chronic Immune Thrombocytopenia (ITP)

    phase 3 small molecule active

    1 trial

  22. KVD900, KVD900

    Pharma Mar S.A.

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  23. KVD900, KVD900

    Pharma Mar S.A.

    Hereditary Angioedema Type I or II

    phase 3 small molecule active

    1 trial

  24. Kreon 35 000 Ph. Eur. Lipase Einheiten, magensaftresistente Hartkapseln

    Pharma Mar S.A.

    Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreatectomy with Pancreatic Exocrine Insufficiency (PEI).

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources